The Supreme Court appeared unsympathetic Monday to a challenge from the maker of flavored e-cigarette products to an FDA decision denying authorization to bring them to market.
The End-of-Phase 2 meeting resulted in alignment with the FDA on the proposed Phase 3 study design, including the inclusion/exclusion criteria, primary and secondary efficacy objectives, definition of ...
Some results have been hidden because they may be inaccessible to you